Brokerages Set Novogen Limited (NASDAQ:KZIA) Target Price at $25.80

Novogen Limited (NASDAQ:KZIA) has earned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $25.80.

Several analysts recently issued reports on KZIA shares. Lake Street Capital began coverage on shares of Novogen in a research note on Thursday, June 11th. They set a “buy” rating and a $32.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Novogen in a research note on Friday, July 17th. Laidlaw started coverage on Novogen in a report on Wednesday, April 15th. They set a “buy” rating and a $25.00 target price on the stock. Finally, BTIG Research restated a “buy” rating and issued a $34.00 price target on shares of Novogen in a research report on Wednesday, July 15th.

Novogen Trading Up 1.9%

Shares of NASDAQ KZIA opened at $12.23 on Friday. The firm has a 50-day simple moving average of $13.05 and a 200-day simple moving average of $10.43. Novogen has a 52 week low of $4.86 and a 52 week high of $17.40.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.